Clinical Trials
93
Active:4
Completed:1
Trial Phases
5 Phases
Phase 1:45
Phase 2:30
Phase 3:14
+2 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (92 trials with phase data)• Click on a phase to view related trials
Phase 1
45 (48.9%)Phase 2
30 (32.6%)Phase 3
14 (15.2%)Not Applicable
2 (2.2%)Phase 4
1 (1.1%)A Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Other Solid Tumors
Not Applicable
Not yet recruiting
- Conditions
- Non-small Cell Lung CancerSolid Tumor
- Interventions
- First Posted Date
- 2025-07-09
- Last Posted Date
- 2025-07-09
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 31
- Registration Number
- NCT07056556
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China
A Study of BL-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metastatic Cervical Cancer and Endometrial Cancer
Not Applicable
Not yet recruiting
- Conditions
- Cervical CancerEndometrial Cancer
- Interventions
- First Posted Date
- 2025-07-08
- Last Posted Date
- 2025-07-08
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 206
- Registration Number
- NCT07054567
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer
Phase 3
Not yet recruiting
- Conditions
- Epithelial Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer
- Interventions
- Drug: Liposomal doxorubicin, Paclitaxel or Topotecan
- First Posted Date
- 2025-05-29
- Last Posted Date
- 2025-05-29
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 540
- Registration Number
- NCT06994195
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
A Study of BL-B01D1 Combined With Lenvatinib in Patients With Advanced Hepatocellular Carcinoma
Phase 2
Not yet recruiting
- Conditions
- Advanced Hepatocellular Carcinoma
- Interventions
- First Posted Date
- 2025-05-23
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 46
- Registration Number
- NCT06986785
- Locations
- 🇨🇳
Zhongshan Hospital Fudan University, Shanghai, Shanghai, China
A Study of BL-B01D1+PD-1/PD-L1 Monoclonal Antibody in Patients With Advanced Biliary Tract Cancer
Phase 2
Recruiting
- Conditions
- Advanced Biliary Tract Cancer
- Interventions
- First Posted Date
- 2025-05-18
- Last Posted Date
- 2025-07-02
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 46
- Registration Number
- NCT06978114
- Locations
- 🇨🇳
Zhongshan Hospital Fudan University, Shanghai, Shanghai, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 19
- Next
News
No news found